Viracta Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
Viracta Therapeutics, Inc. (VIRX)
Company Research
Source: GlobeNewswire
Presented positive topline Nana-val results from Stage 1 of the pivotal Phase 2 NAVAL-1 trial in patients with relapsed or refractory (R/R) Epstein-Barr virus-positive (EBV+) peripheral T-cell lymphoma (PTCL) Initial results from the ongoing NAVAL-1 trial further validate Nana-val’s “Kick and Kill” mechanism of action; additional data are expected in the third quarter of 2024 Plan to engage with U.S. Food and Drug Administration (FDA) in mid-2024 to align on requirements for accelerated approval and support speed to market strategy Progressed the Phase 1b/2 study of Nana-val in patients with advanced EBV+ solid tumors; on track to determine the recommended Phase 2 dose (RP2D) in the second half of 2024 Positive engagement with the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) enables patients in Japan to be enrolled directly into the NAVAL-1 trial without a preceding Japanese Phase 1 safety/pharmacokinetics study SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- Viracta
Show less
Read more
Impact Snapshot
Event Time:
VIRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VIRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VIRX alerts
High impacting Viracta Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
VIRX
News
- Viracta Therapeutics Announces New Employment Inducement Grants [Yahoo! Finance]Yahoo! Finance
- Viracta Therapeutics Announces New Employment Inducement GrantsGlobeNewswire
- Viracta Therapeutics Appoints Michael Faerm as Chief Financial Officer [Yahoo! Finance]Yahoo! Finance
- Viracta Therapeutics Appoints Michael Faerm as Chief Financial OfficerGlobeNewswire
- Viracta Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance